Article
[Use of Pharmacogenetic Information for Therapeutic Drug Monitoring of an Antiarrhythmic Drug].
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan - 1 Jan 2018
Doki Kosuke
Abstract excerpt
Antiarrhythmic drugs require therapeutic drug monitoring (TDM) to avoid adverse effects such as proarrhythmia. However, TDM is not necessarily used to adjust the dosage of antiarrhythmic drugs because there is a lack of information regarding the therapeutic range of the serum concentration and the selection of patients who require TDM. The aim of this review was to provide an overview of the pharmacogenetic...
Topics
- Adrenergic beta-Antagonists
- Aging
- Anti-Arrhythmia Agents
- Asian People
- Cytochrome P-450 CYP2D6
- Drug Interactions
- Drug Monitoring
- Drug Therapy, Combination
- Flecainide
- Genotype
- Haplotypes
- Heterozygote
- Humans
- NAV1.5 Voltage-Gated Sodium Channel
- Pharmacogenetics
- Polymorphism, Genetic
- Receptors, Adrenergic, beta-1
- Sodium Channel Blockers